Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Open-Label Basket Study of Navicixizumab Monotherapy or in Combination With Paclitaxel or Irinotecan in Patients With Select Advanced Solid Tumors

NCT05453825 is registered in ClinicalTrials.gov with OncXerna Theraputics, Inc. as lead sponsor.

NCT NCT05453825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05453825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Open-Label Basket Study of Navicixizumab Monotherapy or in Combination With Paclitaxel or Irinotecan in Patients With Select Advanced Solid Tumors
Lead sponsor
OncXerna Theraputics, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
August 5, 2022
Completion date
December 15, 2024
Enrollment
180 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, gastric cancer, ovarian cancer, triple negative breast cancer